60 degrees pharma announces irb approval of phase ii study to evaluate tafenoquine for chronic babesiosis

Investigational review board (irb) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. enrollment expected to commence q3 2025.

SXTP Ratings Summary

SXTP Quant Ranking